logo

AMRN

Amarin·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

AMRN fundamentals

Amarin (AMRN) released its earnings on Oct 29, 2025: revenue was 49.67M (YoY +17.43%), beat estimates; EPS was -0.4 (YoY -700.00%), missed estimates.
Revenue / YoY
49.67M
+17.43%
EPS / YoY
-0.4
-700.00%
Report date
Oct 29, 2025
AMRN Earnings Call Summary for Q3,2025
  • U.S. Market Dominance: >50% IPE share sustained with 34% YoY revenue growth, driven by pricing and exclusive PBM regain.
  • Partnership Payoff: Europe transition on track, with $70M OpEx savings flowing through to -22% operating margin (vs. -60% prior year).
  • FDA Label Win: Fenofibrate's cardiovascular benefit removed, creating tailwind for VASCEPA in fibrate-heavy markets.
  • 2026 Outlook: Free cash flow target achievable via reduced OpEx offsetting gross margin decline from partner model.
EPS
Revenue

Revenue & Expenses

AMRN has released its 2025 Q3 earnings report, with revenue of 49.67M, reflecting a YoY change of 17.43%, and net profit of -7.74M, showing a YoY change of 69.21%. The Sankey diagram below clearly presents AMRN's revenue sources and cost distribution.

Key Indicators

Amarin (AMRN) key financial stats and ratios, covering profitability, financial health, and leverage.
Amarin (AMRN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Amarin (AMRN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Amarin (AMRN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Amarin (AMRN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Amarin (AMRN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield